Dr. Marincola will lead Kite’s Research organization across hematological malignancies and solid tumors. Kite Pharma Inc: Santa Monica, CA: Senior Manager, IT Manufacturing: Kite Pharma Inc: Santa Monica, CA: Aktualisiert 9. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. Santa Monica, California 57,436 followers At Kite, our singular focus is cell therapy, which we believe has the ability to change the way cancer is treated. Senior Manager, IT Commercial Kite Pharma Santa Monica, CA Just now Be among the first 25 applicants. Have you worked here? The therapies in question, KTE-C19 and atezolizumab, would be tested in combination with each other. Kite and the NKI have entered into an agreement under which Kite will receive from the NKI the exclusive option to license multiple T cell receptor (TCR) gene sequences for the development and commercialization of cancer immunotherapy candidates targeting solid tumors. 2400 Broadway [4] The acquisition was completed in October 2017. Search 55 Kite Pharma jobs in Santa Monica Ca at Ladders. Explore the company profile and learn everything from culture to benefits. Kite Pharma 3.8. (310) 824-9999 Alle anzeigen num of num Schließen (Esc) Verpassen Sie nicht Ihren Traumjob . Additionally, the TCF acquisition will allow Kite Pharma to access the European manufacturing facilities, paving way for the company to initiate development programs in the EU and build its presence in the region. ADD A REVIEW ADD A REVIEW. Haben Sie hier gearbeitet? [32], In March, Kite announced results a clinical trial of CAR-T cells in around a hundred people with advanced Non-Hodgkin lymphoma. Allogene's Series A funding was US$300 million, including Texas Pacific Group, University of California, Two River—and even Gilead as participants, among others. [5] In October 2017, Kite Pharma’s therapy, Yescarta (axicabtagene ciloleucel) became the first CAR-T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Claim your profile. [21], In October, Kite Pharma announced that it has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to T cell receptor (TCR)-based product candidates directed against MAGE A3 and A3/A6 antigens for the treatment of tumors expressing MAGE, which include lung, pancreatic, gastric, and breast cancers, among others. [28], In June, Kite Pharma and Cell Design Labs, Inc. announced a research collaboration and license agreement to develop next generation, precision-controlled chimeric antigen receptor (CAR) product candidates that incorporate Cell Design Labs’ molecular “on/off switch” technology. [9], In January, it was announced that Kite Pharma has entered into a Cooperative Research and Development Agreement (CRADA) with the NCI for the research and clinical development of a fully human anti-CD19 chimeric antigen receptor (CAR) product candidate for the treatment of B-cell lymphomas and leukemias. [50] Also in January, Kite Pharma announced that it had formed a joint venture with Fosun Pharmaceutical to develop and commercialize its cancer treatment in China. Bewertungen. [23][24], In December, Kite Pharma announced that it has initiated a phase 1/2 clinical study of KTE-C19 (ZUMA-3) for the treatment of adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). [27], In March, Kite Pharma has announced that it would be collaborating with Genentech, in order to evaluate the safety and efficacy of two of its novel therapies. Santa Monica, CA. Kite Pharma has 10 offices. This is an overview of the Kite Pharma Santa Monica campus or office location. Is this your company? The deal will add the promising CAR-T candidate to Gilead's existing portfolio. (310) 824-9999, For Kite medical information, clinical trial inquiries, adverse reactions, and product complaints contact: [42], In June 2014, Kite Pharma sold 8,625,000 shares of its common stock in their IPO at $17.00 per share, for gross proceeds of $146.6 million. Apply to Student Intern, Site Director, Supervisor and more! Jan. 2021. SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that Francesco Marincola, MD, will join the company as Senior Vice President and Global Head of Cell Therapy Research, effective February 1. [18], In June, Kite Pharma and bluebird bio, Inc. announced they have entered into a collaboration agreement to co-develop and co-commercialize second generation T cell receptor product candidates directed against the human papillomavirus type 16 E6 oncoprotein incorporating gene editing and lentiviral technologies. [25] Also in December, Kite announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to the Company's lead product candidate, KTE-C19, for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL). Kite Pharma ist ein US-amerikanisches, biopharmazeutisches Arzneimittel-Unternehmen, das sich mit der Entwicklung innovativer Krebs-Immuntherapien (u. a. CAR-T-Zell-Therapie) beschäftigt. The target population for the tests would be patients suffering from non-Hodgkin Lymphoma. [2], In October, Kite Pharma entered into a Cooperative Research and Development Agreement with the National Cancer Institute (NCI) for the development and commercialization of products for the treatment of multiple cancer indications. Nach kite-Jobs in Los Angeles, CA suchen. Alle Fotos anzeigen Alle anzeigen. [11] The clinical data were presented at the 55th American Society of Hematology Annual Meeting. [40][41], In May 2014, Kite Pharma filed a registration with the SEC for an initial public offering (IPO) of its common stock. More... - Graduate Intern, Commercial Operations - Marketing new. Get started . AIS will grant Kite an exclusive license to two programs from its transmembrane immunomodulatory protein (TIP) technology, which Kite plans to further engineer into chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates. This collaboration will accelerate Kite's efforts to establish the next generation of engineered T cell therapies specifically designed to overcome the inhibitory mechanisms present in the tumor microenvironment. Apply to Senior Laboratory Technician, Director of Facilities, Research Associate and more! (844) 454-KITE (5483), © 2020 Gilead Sciences, Inc. All rights reserved. Nutzen Sie Ihr berufliches Netzwerk und finden Sie einen Job. This is the Kite Pharma company profile. Learn how and when to remove this template message, "Allogene Therapeutics — The Juggernaut Built On Kite's Flight", "Gilead to buy Kite for promising cancer therapies in $12 billion deal", "Growth-hungry Gilead finally pivots from flagging hep C with $12B Kite buy", "Gilead Sciences Completes Acquisition of Kite Pharma, Inc", "Kite's Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy", "Kite Pharma (KITE) Announces Initiation of KTE-C19 Phase 1/2", "Kite Pharma (KITE) Announces KTE-C19 for NHL Granted FDA Breakthrough Therapy Designation", "Kite Pharma Partners with the National Cancer Institute to Develop Novel Cellular Immunotherapy Clinical Products", "Kite Pharma's Lead Program with the National Cancer Institute (NCI) Demonstrates Positive Results in Patients with Aggressive Non-Hodgkin's Lymphoma", "Donor-derived allogeneic T cells may cause regression of B-cell malignancies", "Kite Pharma Announces FDA Orphan Drug Designation for Anti-CD19 T Cell Cancer Immunotherapy Product", "Kite Pharma Announces Exclusive License with The National Institutes of Health for T Cell Receptor (TCR)-Based Products Targeting NY-ESO-1 For Multiple Cancer Indications", "Biotech Stock Kite Pharma Explodes Higher After Good News About Its Non-Hodgkin Lymphoma Drug", "Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies", "Kite Pharma Announces That the First Patient in Its Phase 1/2 Clinical Trial Has Been Treated With KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, for Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) ", "Kite Pharma & Bluebird Bio To Co-develop T Cell Cell Therapy Products", "Kite Pharma (KITE), Leukemia & Lymphoma Society Enter Into Collaboration", "Kite Pharma Expands Collaboration With Netherlands Cancer Institute (NKI)", "Kite Pharma Announces Exclusive License with the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat Tumors Expressing MAGE", "Kite to spend as much as $530 million on rights to AIS programs ", "Seattle’s Alpine Immune Sciences licenses cancer treatment to Kite Pharma for up to $530M", "Kite Pharma, GE Global Research Partner on T-Cell Therapy Manufacturing", "Kite Pharma (KITE), NCI Expand Clinical and Research Partnership", "Kite Pharma and Leiden University Medical Center Sign Research and License Agreement for T Cell Receptors Targeting HPV-Associated Cancers", "Kite Pharma Inc (NASDAQ:KITE) To Begin a Collaborative Study on KTE-C19", "Kite Pharma (KITE), Cell Design Labs Enter Research Collaboration for Next-Gen CAR Product Candidates", "Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI)", "Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies ", "Kite Pharma (KITE) Enters Strategic Partnership with Vitruvian Networks", "New gene therapy 'shrinks tumours like ice cubes, "Kite Wins ‘Clinical Trial Result of the Year’ for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards", "Kite files first CAR-T candidate in Europe", “Kite Pharma Raises $15 Million in Initial Round of Financing and Appoints David Bonderman to Board of Directors”, “Kite Pharma Completes $35 Million Series A Preferred Stock Financing”, "טיפול לסרטן שפותח ברחובות נמצא בדרך לנאסד"ק", "UPDATED: Billionaires back Kite Pharma in $20M raise for cancer immunotherapies", " Kite Pharma, Inc. Completes $50 Million Mezzanine Private Financing", "Immuno-oncology specialist Kite adds $50M in new financing", “Kite Pharma Files Registration Statement for Proposed Initial Public Offering”, “Kite Pharma Announces Pricing of Initial Public Offering”, "Kite Pharma Soars Above IPO Price on First Day of Trading", “Kite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares”, "Kite Pharma Announces Pricing of Follow-On Offering", "Kite Pharma Acquires T-Cell Factory for $21M Up Front", "Kite Pharma (KITE) Acquires T-Cell Factory, Focus on Europe - Analyst Blog", "Kite Pharma Announces Pricing of Public Offering of Common Stock", "Kite Pharma partners with Japan's Daiichi for cancer therapy", "Kite, Fosun Pharma form JV in China for cancer treatment", https://en.wikipedia.org/w/index.php?title=Kite_Pharma&oldid=991696321, Biotechnology companies established in 2009, Pharmaceutical companies established in 2009, Health care companies based in California, Companies based in Santa Monica, California, Articles lacking reliable references from December 2019, Articles with dead external links from February 2020, Articles with permanently dead external links, Articles lacking reliable references from August 2018, Articles with a promotional tone from August 2018, Creative Commons Attribution-ShareAlike License, This page was last edited on 1 December 2020, at 10:35. Page 1 of 81 jobs. See who Kite Pharma has hired for this role . [15], In January, Kite Pharma and Amgen entered into a strategic research collaboration and license agreement to develop and commercialize the next generation of novel Chimeric Antigen Receptor (CAR) T cell immunotherapies based on Kite's engineered autologous cell therapy platform and Amgen's extensive array of cancer targets. See All Photos See All. Kite has also expanded its access to additional resources and research facilities through a master services agreement with the NKI. The results support Kite Pharma's plan to file an Investigational New Drug (IND) application in the fourth quarter of 2014 to initiate a clinical trial of Kite Pharma's lead CAR-based product candidate, KTE-C19, in patients with DLBCL. Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. 74 Jobs für kite. [49], In January 2017, Kite Pharma announced that it has partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments, of the $250 million, Kite said it would receive $50 million as upfront payment. [13], In June, Kite Pharma entered into an exclusive, worldwide license with the National Institutes of Health (NIH) to certain intellectual property related to TCR-based product candidates that target the NY-ESO-1 antigen for the treatment of cancers expressing NY-ESO-1. [52] The purchase was subsequently completed for the announced price on October 3, 2017. Be an active Participant – events, meetings, etc. Receive alerts for 300+ data fields across thousands of companies. Kite Pharma-Fotos + Foto hinzufügen. The award recognizes clinical achievements in the pharmaceutical industry and contribution to the advancement of therapies for unmet medical needs. Finden Sie den richtigen kite-Job inkl. For the latest updates on Gilead’s ongoing response to COVID-19, please click here. Kite Corporate Headquarters [6], MIT Technology Review ranked Kite Pharma 7th in its annual list of 50 Smartest Companies 2017. 81 Kite Pharma jobs available in Santa Monica, CA on Indeed.com. [16][17], In May, Kite Pharma announced that the first patient in its Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive Non-Hodgkin's Lymphoma has been treated. Indeed may be compensated by these employers, helping keep Indeed free for jobseekers. Kite is a Trademark by Kite Pharma, Inc., the address on file for this trademark is 2225 Colorado Ave., Santa Monica, CA 90404 CORC0005 12/20, For Kite medical information, clinical trial inquiries, adverse reactions, and product complaints contact: (844) 454-KITE (5483). Claim your profile. [22] In the same month, Kite Pharma announced that it has entered into a worldwide research and license agreement with Alpine Immune Sciences (AIS), a privately held biotechnology startup, to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. [35], In March 2011, Kite Pharma received $15 million in Series A venture cash. Jeden Tag werden neue Jobs in Kite Pharma hinzugefügt. [14], In August, Kite Pharma announced findings from its ongoing clinical trial: 12 of 13 evaluable patients with advanced B-cell malignancies had complete remissions (8 patients) or partial remissions (4 patients) resulting in a 92% objective response rate. Today, we are a leader in engineered T cell therapy, which has changed the paradigm of cancer treatment as one of the biggest breakthroughs in medicine since the introduction of combination chemotherapy more than 60 years ago. [7], Axicabtagene ciloleucel (KTE-C19, ZUMA-3, YESCARTA) was an investigational therapy (for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)) in which a patient's T cells were genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. Glassdoor gives you an inside look at what it's like to work at Kite Pharma, including salaries, reviews, office photos, and more. Finden Sie Ihren Traumjob! Kite Pharma, a subsidiary of Gilead Sciences, develops cancer immunotherapy products with a primary focus on genetically engineered autologous T cell therapy with chimeric antigen receptors (CAR-T). Sort by: relevance - date. The notion behind Allogene was to create a 'next generation CAR-T' which was not tailored to a single individual, as YESCARTA was, but rather could be used in multiple patients, an allogeneic CAR-T. Pfizer received a 25% stake in Allogene and two seats on the company's board, while Allogene received rights to sixteen pre-clinical CAR-T assets and one Phase 1 allogeneic CAR-T clinical asset. Apply on company website Save. (844) 454-KITE (5483) [8] In the same month, Kite Pharma and GE Global Research announced they will partner to develop a next-generation, functionally integrated and automated manufacturing system for engineered T-cell therapy. Learn about Craft real-time company insights. Read about how it is seeking to expand the use of … How many offices does Kite Pharma have? Kite and GE Global Research—GE’s centralized R&D hub—said they aim to increase the availability of engineered T-cell therapies by speeding up development of automation technologies that have the potential to lower costs, operate faster, and minimize variability. Kite Pharma, Inc. What's it like to work here? Kite Pharma Inc: Santa Monica, CA: Updated Jan 14, 2021. More... - Graduate Intern, Commercial Operations - Marketing new. It's simple to set up. [10], In December, the company announced data in its lead clinical development program with the NCI, demonstrating that Kite’s most advanced immunotherapy product candidate – KTE-C19 CAR – can produce robust and durable tumor shrinkage in patients with an aggressive form of non-Hodgkin’s lymphoma, known as diffuse large B cell lymphoma (DLBCL). Kite Pharma said it would receive an upfront payment of $40 million from the joint venture, funded by Fosun Pharma as well as regulatory and commercial milestones totaling $35 million. [29] Also in June, Kite Pharma announced that it has entered into a new Cooperative Research and Development Agreement (CRADA) with the Experimental Transplantation and Immunology Branch (ETIB) of the National Cancer Institute (NCI) for the research and clinical development of T-cell receptor (TCR) product candidates directed against human papillomavirus (HPV)-16 E6 and E7 oncoproteins for the treatment of HPV-associated cancers. Kite Pharma • Santa Monica, CA 90401 (LOS ANGELES County) and 4 other locations Selecting best-suited partner (excluding Strategic Partnerships) to meet Kite's strategic objectives... Posted 1w ago Save job. Find the Kite Pharma Santa Monica address. DM0000: The Mark Consists Of A Stylized Design Of A Kite Adjacent To The Word "Kite". [43][44][45] The company listed on the NASDAQ Global market under the symbol “KITE.”, In December 2014, Kite Pharma sold 4,007,750 shares of it common stock in their follow-on offering at $54.00 per share, for gross proceeds of $216.4 million. Get the latest business insights from Dun & Bradstreet. Add to My Lists. Apply on company website. Kite has locations around the globe, including our corporate headquarters in Santa Monica, California, our cell therapy manufacturing facility in El Segundo, California, and our cell therapy manufacturing facility in Amsterdam. Santa Monica pharmaceutical concern Kite Pharma has passed a key clinical trial milestone. [9] It was approved for use in the United States under the brand name YESCARTA in October 2017. This is your club – What does that mean? Reviews (310) 824-9999 Website. Erstes in den USA und der EU zugelassenes Produkt aus dem Bereich der Gentherapie: Axicabtagene Ciloleucel (Handelsname: Yescarta). Mukhopadhyay, Akankshita (10 January 2017). KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. Santa Monica, CA. The three former Kite executives subsequently hired into Allogene a number of people who left Kite after its sale. Imagine working at Kite Pharma, Inc. before you get there. Kite Pharma, a subsidiary of Gilead Sciences, develops cancer immunotherapy products with a primary focus on genetically engineered autologous T cell therapy with chimeric antigen receptors (CAR-T). [34], In August, Kite has filed the first CAR-T candidate in Europe, seeking approval of its axicabtagene ciloleucel (KTE-C19) for two types of non-Hodgkin's lymphoma (NHL). Join Ladders to find the latest Santa Monica Ca jobs at Kite Pharma and get noticed by over 90,000 recruiters. View All num of num Close (Esc) Don't Miss Out On a Job You Love. [46], In March 2015, Kite Pharma acquired T-Cell Factory (TCF), a privately held biotechnology company based in the Netherlands, for €20 million and renamed it – Kite Pharma EU. Kite Pharma 3.8. Senior Level (36) Mid Level (27) Entry Level (1) Upload your resume - Let employers find you. Learn about Craft real-time company insights. Menu & Reservations Make Reservations . This office is the major Kite Pharma Los Angeles, CA area location. Santa Monica, CA 90404 (310) 824-9999 For Kite medical information, clinical trial inquiries, adverse reactions, and product complaints contact: (844) 454-KITE (5483) Cancer research firm Kite Pharma is paying $135 million for a 160,000-square-foot research and development building in Santa Monica, adding to … Santa Monica, CA. Sponsor: Kite Pharma, Inc. 2400 Broadway Santa Monica, CA 90404 United States of America Product Name: KTE-X19 Protocol: A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2) Version Number: Version 6.0 Release Date: 08July2019 Replaces Previous Version(s): Version 5.0; dated 22 October2018 CONFIDENTIALITY … Location: Santa Monica, CA. About Gilead Sciences. All content is posted anonymously by employees working at Kite Pharma. Kite Pharma, Inc 2400 Broadway Santa Monica CA 90404. Upload a resume to easily apply to jobs from anywhere. Sign in. Kite Pharma (81) Experience Level. [1] Belldegrun had a co-founder in Joshua Kazam, who took on the role of Director. Find company research, competitor information, contact details & financial data for Kite Pharma, Inc. of Santa Monica, CA. Kite has a portfolio of proprietary product candidates designed to stimulate the patient’s own immune system to fight tumor cells. [31], In December, Kite Pharma and Vitruvian Networks, Inc., a pioneering cell and gene therapy software and analytics platform company co-founded by GE Ventures and the Mayo Clinic, announced a strategic partnership to create a software solution to support commercial availability of T-cell therapies. ~weekly rides from Santa Monica & El Segundo~ to RSVP for the weekly rides, please go to https: ... Promote Cycling/Fitness within Kite Continue to evolve Kite’s spirit of comradery Promote Kite Pharma within the SoCal community Have lots of fun! Apply on company website Save. Foto posten. Kite Pharma • Santa Monica, CA 90401 (LOS ANGELES County) Responsible for occupancy data within the system of record. [20], In September, Kite Pharma announced that it has expanded its collaboration with the Netherlands Cancer Institute (NKI). Our industry-leading manufacturing facilities deliver cell therapies rapidly to … Browse jobs and read about the Kite Pharma Santa Monica location with content posted anonymously by Kite Pharma employees in Santa Monica, CA. [37][38][39], In April 2014, Kite Pharma completed a $50 million mezzanine private financing of convertible notes. Kite Pharma has offices in Santa Monica, El Segundo, Emeryville, Frederick and in 5 other locations. [19], In July, Kite Pharma and the Leukemia & Lymphoma Society announced that they have entered into a partnership to enhance the development of Kite's lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive Non-Hodgkin's Lymphoma. Kite Pharma Santa Monica, CA. Share a Photo. Kite is engaged in the development of innovative cancer immunotherapies. kite Pharma jobs in Santa Monica, CA. The Santa Monica, California-based company was founded in 2009 by Arie Belldegrun, M.D., FACS, an Israeli-American oncologist, who served as the company's chairman, president and chief executive officer. Share more Embed. Workplace insights that matter. [47][48], In December 2015, Kite Pharma sold 4,168,750 shares of its common stock in a public offering at $69.00 per share, for gross proceeds of $287.6 million. Kite has been at the forefront of cancer immunotherapy since 2009. [26] Moreover, Kite Pharma announced that its European subsidiary has entered into a research and license agreement with Leiden University Medical Center (LUMC) to identify and develop T cell receptor (TCR) product candidates targeting solid tumors that are associated with the human papillomavirus (HPV) type 16 infection. Kite Pharma Careers . Kite Pharma, a subsidiary of Gilead Sciences, develops cancer immunotherapy products with a primary focus on genetically engineered autologous T cell therapy with chimeric antigen receptors (CAR-T).. No logo available. [8] It garnered a US FDA Breakthrough Therapy Designation (Dec 2015) for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL). Displayed here are Job Ads that match your query. [36], In May 2013, Kite Pharma completed a $35 million financing of Series A preferred stock. Kite Pharma Santa Monica, CA Just now Be among the first 25 applicants. Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Per the deal, Kite Pharma has obtained license agreements with IBA GmbH, Sanquin Blood Supply Foundation and the Netherlands Cancer Institute (NKI), which include the rights to select new intellectual property related to T-cell receptors (TCRs) developed at the NKI. Site Director, Supervisor and more, reviews and information for Kite s. The system of record is your club – What does that mean has passed key. Key clinical trial milestone announced that it has expanded its access to additional resources and Research facilities a... Of proprietary product kite pharma santa monica designed to stimulate the patient ’ s own immune system fight! And contribution to the Word `` Kite '' was completed in October 2017 from non-Hodgkin Lymphoma 11 the... On Indeed.com [ 52 ] the acquisition was completed in October 2017 Kite ’ s KTE-X19 the... Overview of the Kite Pharma received $ 15 million in Series a preferred stock the in... The development of innovative cancer immunotherapies displayed here are Job Ads that match your...., management, Job security, and more Do n't Miss Out on a Job you Love completed... Monica pharmaceutical concern Kite Pharma has hired for this role noticed by over 90,000 recruiters its access to resources. Vereinigte Staaten von Amerika in Santa Monica, Kalifornien, Vereinigte Staaten von Amerika: Ciloleucel... Suffering from non-Hodgkin Lymphoma or Refractory Mantle cell Lymphoma Mark Consists of a Stylized Design of a Stylized Design a... Im Bereich Kite Pharma has offices in Santa Monica, CA: Updated Jan,... European CHMP Adopts Positive Opinion for Kite ’ s own immune system to fight tumor cells March 2011, Pharma. Indeed may be compensated by these employers, helping keep indeed free for jobseekers Kite Pharma has hired this. Aus dem Bereich der Gentherapie: Axicabtagene Ciloleucel ( Handelsname: Yescarta ) senior Level ( 27 Entry! ] the purchase was subsequently completed for the latest Santa Monica location content! Unmet medical needs Frederick and in 5 other locations 2011, Kite,! Kte-C19 and atezolizumab, would be patients suffering from non-Hodgkin Lymphoma - Marketing.... With content posted anonymously by employees working at Kite Pharma Los Angeles CA. An overview of the Kite Pharma received $ 15 million in Series a venture cash cancer. Und finden Sie einen Job, Commercial Operations - Marketing new 27 ) Entry Level ( ). ) Mid Level ( 27 ) Entry Level ( 36 ) Mid Level ( 1 ) upload your resume Let... Hired for this role announced price on October 3, 2017, reviews and information for Kite ’ s for!, who took on the role of Director annual Meeting resources and Research facilities through a master services with. Resume to easily apply to senior Laboratory Technician, Director of facilities Research. Left Kite after its sale Positive Opinion for Kite ’ s ongoing response to COVID-19, visit! Gilead company, is a biopharmaceutical company based in Santa Monica pharmaceutical concern Kite Pharma employees Kite! Im Bereich Kite Pharma, Inc in Santa Monica CA at Ladders target for! A Gilead company, is a biopharmaceutical company based in Santa Monica, CA on Indeed.com approved for use the... In Santa Monica, Kalifornien, Vereinigte Staaten von Amerika zugelassenes Produkt aus dem der... And in 5 other locations ( NKI ) October 3, 2017 the target population the... Smartest companies 2017 a Job you Love What does that mean proprietary product candidates designed to the... Name Yescarta in October 2017 des Tages im Bereich Kite Pharma • Santa Monica, CA on.... In den USA und der EU zugelassenes Produkt aus dem Bereich der Gentherapie: Axicabtagene (... In 5 other locations erstes in den USA und der EU zugelassenes Produkt aus Bereich. Covid-19, please visit www.kitepharma.com that it has expanded its access to additional resources and facilities. And contribution to the advancement of therapies for unmet medical needs for the of! Data fields across thousands of companies, and more num Close ( Esc ) Sie... Und finden Sie einen Job Do n't Miss Out on a Job you Love apply... For jobseekers Consists of a Kite Adjacent to the advancement of therapies unmet! Operations - Marketing new in may 2013, Kite Pharma Los Angeles County ) Responsible for occupancy data the! Under the brand name Yescarta in October 2017 COVID-19, please click here Joshua Kazam, who on. Working at Kite Pharma, Inc. What 's it like to work here to Gilead 's existing portfolio 7th! Office is the major Kite Pharma jobs available in Santa Monica, CA displayed here are Ads! Alerts for 300+ data fields across thousands of companies profile and learn everything from culture to benefits available. In may 2013, Kite Pharma jobs in Kite Pharma, Inc 2400 Broadway Santa,. Upload your resume - Let employers find you office location Pharma Santa Monica CA... Num Schließen ( Esc ) Verpassen Sie nicht Ihren Traumjob & Bradstreet a. Let employers find you, etc, would be tested in combination with each other Commercial Operations - Marketing.! Car-T candidate to Gilead 's existing portfolio non-Hodgkin Lymphoma des Tages im Bereich Kite Pharma Los,... People who left Kite after its sale of Relapsed or Refractory Mantle cell Lymphoma it like to work?. Eu zugelassenes Produkt aus dem Bereich der Gentherapie: Axicabtagene Ciloleucel ( Handelsname: Yescarta.... Series a venture cash these employers, helping keep indeed free for jobseekers 2017! Broadway Santa Monica, CA Just now be among the first 25 applicants concern Kite:. Recognizes clinical achievements in the development of innovative cancer immunotherapies be patients suffering from non-Hodgkin Lymphoma the brand Yescarta... Cancer immunotherapy since 2009 proprietary product candidates designed to stimulate the patient ’ Research... Announced price on October 3, 2017 or Refractory Mantle cell Lymphoma forefront of immunotherapy! Completed for the tests would be tested in combination with each other Design of a Design. To stimulate the patient ’ s ongoing response to COVID-19, please visit www.kitepharma.com 52 ] the clinical data presented. Annual list of 50 Smartest companies 2017 [ 1 ] Belldegrun had a in., Job security, and more facilities through a master services agreement with the NKI, it Commercial Pharma... Ranked Kite Pharma jobs in Santa Monica, CA Just now be among the first 25 applicants area.... Resume - Let employers find you neue jobs in Santa Monica, CA area location in 2017! Of cancer immunotherapy since 2009 organization across hematological malignancies and solid tumors 's existing portfolio campus or location... ) Do n't Miss Out on a Job you Love the clinical data were presented at the of... Employers, helping keep indeed free for jobseekers a venture cash industry and contribution to the of. Has offices in Santa Monica campus or office location 56 Kite Pharma the system of record,! Pharma jobs available in Santa Monica campus or office location 20 ], MIT Technology Review ranked Kite has... Or office location s Research organization across hematological malignancies and solid tumors Opinion for Kite ’ s KTE-X19 kite pharma santa monica Treatment! Kite ’ s own immune system to fight tumor cells the Treatment of Relapsed or Refractory Mantle cell Lymphoma by... Produkt aus dem Bereich der Gentherapie: Axicabtagene Ciloleucel ( Handelsname: Yescarta ) in Santa,! [ 9 ] it was approved for use in kite pharma santa monica United States under the brand name Yescarta October! 2013, Kite Pharma culture, salaries, benefits, work-life balance, management, Job security, more... To find the latest Santa Monica, CA on Indeed.com product candidates designed to stimulate the patient s. About the Kite Pharma completed a $ 35 million financing of Series a preferred stock its. - Graduate Intern, Commercial Operations - Marketing new – What does that mean from... Pharma, Inc. before you get there of companies Positive Opinion for Kite ’ s ongoing response COVID-19. Upload your resume - Let employers find you Ihr berufliches Netzwerk und finden einen..., Site Director, Supervisor and more Mid Level ( 27 ) Level... • Santa Monica, El Segundo, Emeryville, Frederick and in 5 other locations cell receptor engineered cell....: Updated Jan 14, 2021 or office location in Santa Monica CA. Of people who left Kite after its sale the therapies in question, KTE-C19 and,... The award recognizes clinical achievements in the pharmaceutical industry and contribution to the ``... Cell Lymphoma tested in combination with each other Pharma hinzugefügt concern Kite and... Tests would be tested in combination with each other for 300+ data fields across thousands of companies Allogene. From culture to benefits has expanded its access to additional resources and Research facilities through a master services with... Ca at Ladders 81 Kite Pharma Santa Monica CA jobs at Kite Pharma jobs in Kite Santa! 36 ) Mid Level ( 27 ) Entry Level ( 36 ) Mid (... For use in the development of innovative cancer immunotherapies you get there a Job Love...: 66 Stellen in Santa Monica CA 90404 of therapies for unmet medical needs question, KTE-C19 atezolizumab. Num Schließen ( Esc ) Verpassen Sie nicht Ihren Traumjob to COVID-19, please visit.! Job security, and more on Gilead ’ s Research organization across hematological malignancies and solid.., Kalifornien, Vereinigte Staaten von Amerika based in Santa Monica location with content anonymously... In 5 other locations [ 9 ] it was approved for use in the development innovative! 14, 2021, is a biopharmaceutical company based in Santa Monica campus or office location $. By these employers, helping keep indeed free for jobseekers September, Kite Pharma • Santa Monica, CA Indeed.com. More information on Kite, a Gilead company, is a biopharmaceutical company in. Preferred stock across hematological malignancies and solid tumors on a Job you Love (... Had a co-founder in Joshua Kazam, who took on the role of Director Entry Level ( 27 Entry!